Feasibility Study of Intraoperative Detection of Residual Cancer in Breast Cancer Patients

PHASE2TerminatedINTERVENTIONAL
Enrollment

98

Participants

Timeline

Start Date

September 1, 2020

Primary Completion Date

November 30, 2023

Study Completion Date

February 29, 2024

Conditions
Breast CancerNeoadjuvant Therapy
Interventions
DRUG

LUM015

LUM015 will be administered 2 to 6 hours prior to surgery for both arms. The LUM Imaging device will be used to assist in the removal of additional tumor tissue in the device intervention arm.

DEVICE

Lum Imaging System

UM015 will be administered 2 to 6 hours prior to surgery for both arms. The LUM Imaging device will be used to assist in the removal of additional tumor tissue in the device intervention arm.

Trial Locations (6)

27103

Novant Health Cancer Center, Winston-Salem

27710

Duke Cancer Center, Durham

33756

Morton Plant Mease Health Care Oncology Research, Clearwater

77030

The University of Texas MD Anderson Cancer Center, Houston

94304

Stanford Hospital and Clinics, Palo Alto

02114

Massachusetts General Hospital, Boston

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Lumicell, Inc.

INDUSTRY